Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 8/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482205 | 1.00 | KCNA5 (0.44) | KCNA5HPGDTDP1ALDH1A1LMNA | |
| SCHEMBL9742155 | 0.86 | KCNA5 (0.40) | KCNA5HPGDALDH1A1 | |
| SCHEMBL7048877 | 0.81 | KDM4E (0.41) | — | |
| SCHEMBL7693611 | 0.81 | KDM4E (0.41) | — | |
| SCHEMBL7048882 | 0.81 | KDM4E (0.41) | — | |
| SCHEMBL9876495 | 0.81 | ALDH1A1 (0.41) | TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL10816515 | 0.80 | CTNNB1 (0.37) | KCNA5 | |
| SCHEMBL482263 | 0.78 | ABCC9 (0.49) | HPGDTDP1ALDH1A1MAPT | |
| SCHEMBL482265 | 0.78 | ABCC9 (0.49) | HPGDTDP1ALDH1A1MAPT | |
| SCHEMBL10956358 | 0.78 | ALOX5 (0.45) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KCNA5 19/4885HPGD 1421/4885TDP1 3268/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KCNA5 19/4885HPGD 1421/4885TDP1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.